GATC Health Corp. announced a groundbreaking stem cell therapy for diabetes, detailed in a recent publication in the American Journal of Biomedical Science & Research.
This autologous therapy uses a patient’s own stem cells to potentially treat both Type 1 and Type 2 diabetes, offering improved blood sugar control and reduced medication dependence.
The process is aided by GATC Health’s AI platform, MAT, for patient selection and monitoring.
Early clinical trial results show the therapy to be safe and effective, with benefits lasting up to 36 months.
Further research is planned to optimize the treatment and explore its application in other diseases.
Listen to our latest podcast episode for more info…
Read full paper here: https://biomedgrid.com/pdf/AJBSR.MS.ID.003314.pdf